Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 2 (Q58416764)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 2 |
article |
Statements
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248) (English)
Hedy Teppler
Rebecca Gelman
Deborah Weng Cherng
Ian Frank
Donna Mildvan
Barbara Schock
Mary A Vogler
Michael M Lederman
Richard B Pollard
Charles J Gonzalez
Kathleen E Squires
Laura F Mahon
AIDS Clinical Trials Group 248 Study Team